L Peremans, M Twilt, A Fifi-Mah, N Johnson, D Mosher, A Wade, L Hamiwka
{"title":"Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.","authors":"L Peremans, M Twilt, A Fifi-Mah, N Johnson, D Mosher, A Wade, L Hamiwka","doi":"10.1186/s12969-025-01147-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Takayasu arteritis (TAK) is a rare granulomatous inflammatory vasculitis primarily affecting the aorta and its major branches. Data on childhood-onset TAK (c-TAK) remain scarce. This study retrospectively evaluates the clinical presentation, disease flares, treatment, and outcomes of c-TAK in a tertiary Canadian center.</p><p><strong>Methods: </strong>We identified all children under 18 years of age at disease onset with a clinical diagnosis of TAK seen at Alberta Children's Hospital, Calgary, Canada, between 2000 and 2024. Patients meeting the EULAR/PRINTO/Pres classification criteria for c-TAK were included. Baseline demographic data, clinical presentation, laboratory findings, imaging results, disease flares, and treatment were documented. Additionally, we highlight two challenging cases due to their particularly complex disease trajectories.</p><p><strong>Results: </strong>Six children (4 female) with a median age at diagnosis of 14.5 years (range: 4-17) met the classification criteria for c-TAK. Clinical presentation was variable, with the most common symptoms being fatigue (n = 4), weight loss (n = 3), and hypertension (n = 3). The most frequently affected arteries were the abdominal aorta and carotid arteries (n = 5) followed by ascending aorta (n = 4). All patients received corticosteroids for induction treatment. Additional immunosuppressive therapies included methotrexate (n = 5), infliximab (n = 2), tocilizumab (n = 2), IVIG (n = 2), etanercept (n = 1), adalimumab (n = 1), and cyclophosphamide (n = 1).</p><p><strong>Conclusions: </strong>TAK is a rare, potentially life-threatening large-vessel vasculitis. Early recognition is crucial for timely diagnosis and aggressive treatment initiation. Children with TAK often experience a complex disease course requiring multiple treatment adjustments and surgical or endovascular interventions. Large, multinational collaborations are essential for advancing our knowledge and improving patient outcomes.</p>","PeriodicalId":54630,"journal":{"name":"Pediatric Rheumatology","volume":"23 1","pages":"94"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12969-025-01147-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Takayasu arteritis (TAK) is a rare granulomatous inflammatory vasculitis primarily affecting the aorta and its major branches. Data on childhood-onset TAK (c-TAK) remain scarce. This study retrospectively evaluates the clinical presentation, disease flares, treatment, and outcomes of c-TAK in a tertiary Canadian center.
Methods: We identified all children under 18 years of age at disease onset with a clinical diagnosis of TAK seen at Alberta Children's Hospital, Calgary, Canada, between 2000 and 2024. Patients meeting the EULAR/PRINTO/Pres classification criteria for c-TAK were included. Baseline demographic data, clinical presentation, laboratory findings, imaging results, disease flares, and treatment were documented. Additionally, we highlight two challenging cases due to their particularly complex disease trajectories.
Results: Six children (4 female) with a median age at diagnosis of 14.5 years (range: 4-17) met the classification criteria for c-TAK. Clinical presentation was variable, with the most common symptoms being fatigue (n = 4), weight loss (n = 3), and hypertension (n = 3). The most frequently affected arteries were the abdominal aorta and carotid arteries (n = 5) followed by ascending aorta (n = 4). All patients received corticosteroids for induction treatment. Additional immunosuppressive therapies included methotrexate (n = 5), infliximab (n = 2), tocilizumab (n = 2), IVIG (n = 2), etanercept (n = 1), adalimumab (n = 1), and cyclophosphamide (n = 1).
Conclusions: TAK is a rare, potentially life-threatening large-vessel vasculitis. Early recognition is crucial for timely diagnosis and aggressive treatment initiation. Children with TAK often experience a complex disease course requiring multiple treatment adjustments and surgical or endovascular interventions. Large, multinational collaborations are essential for advancing our knowledge and improving patient outcomes.
期刊介绍:
Pediatric Rheumatology is an open access, peer-reviewed, online journal encompassing all aspects of clinical and basic research related to pediatric rheumatology and allied subjects.
The journal’s scope of diseases and syndromes include musculoskeletal pain syndromes, rheumatic fever and post-streptococcal syndromes, juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, local and systemic scleroderma, Kawasaki disease, Henoch-Schonlein purpura and other vasculitides, sarcoidosis, inherited musculoskeletal syndromes, autoinflammatory syndromes, and others.